Improving Clinical and Economic Outcomes with Emerging Therapies in the Management of Chronic Lymphocytic Leukemia (CLL)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Acerta Pharma - A member of the AstraZeneca Group,
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech,
and Verastem Oncology

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow and is the most common type of leukemia in adults. CLL affects B cell lymphocytes, which originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. Patients with CLL have impaired immune systems and multiple comorbidities, which can complicate management and impact treatment decisions. Furthermore, patients with CLL are often diagnosed when they are asymptomatic; therefore, knowing when to initiate treatment may pose a challenge to clinicians. Several new treatments have become available in the last few years, giving clinicians many new options to improve patient outcomes. Additionally, some of these new options have had recent advances which have opened up the number of patients who are eligible to receive these treatments. This presentation focuses on these evolving options, outlines how to incorporate quality measures for the diagnosis and management of CLL, and describes how to apply evidence-based data to select appropriate treatment regimens and manage toxicities.

Upon completion of this activity, participants will be able to:

  • Analyze the safety and efficacy profiles of emerging therapies in the management of chronic lymphocytic leukemia (CLL)

  • Examine the role of current and next generation BTK inhibitors in the management of CLL

  • Evaluate the role of emerging PI3K inhibitors in the management of CLL

  • Review individualized treatment algorithms in frontline CLL based on clinical data and patient health status

  • Explore ways to incorporate the current and emerging CLL treatment options into the current paradigm of care for patients with CLL, including the management of complications related to resistance, relapse, and immune-related adverse events

  • Assess the managed care considerations of BTK and PI3k inhibitors by exploring where these agents fit in the evolving CLL treatment paradigm

Faculty: John Allan, MD
Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine


Dr. Allan serves on an advisory board for Abbvie, Acerta, Bayer, Genentech, Pharmacyclics, Sunesis, and Verastem. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Acerta Pharma - A member of the AstraZeneca Group,
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech,
and Verastem Oncology

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue